FDA Approves Bizengri for Rare Bile Duct Cancer Under Priority Program

The FDA granted approval for Bizengri (zenocutuzumab-zbco), marking the seventh approval under the National Priority Voucher Pilot Program. The drug treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare and aggressive cancer of the bile ducts.